Clinical Trial Update: Determine the Safety of a Sublingual Tablet Formulation of Buprenorphine and Naloxone by Extending the Combination Tablet Availability to Physicians in Office-Based Practice [Phase 4]

View source ↗

Summary

This Phase 4 study evaluated the safety of a buprenorphine/naloxone sublingual tablet and examined extending its availability to physicians in office-based prac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid Use Disorder

Drugs mentioned

• SUBOXONE (buprenorphine hydrochloride, naloxone hydrochloride)

Snippet

Sponsor: US Department of Veterans Affairs | Conditions: Opiate Dependence | Phase 4 | Status: COMPLETED